<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843072</url>
  </required_header>
  <id_info>
    <org_study_id>BASELINE TRIAL</org_study_id>
    <nct_id>NCT04843072</nct_id>
  </id_info>
  <brief_title>Balloon vs. Self Expanding Transcatheter Valve for Degenerated Bioprosthesis</brief_title>
  <acronym>BASELINE</acronym>
  <official_title>Balloon Expandable vs. Self Expanding Transcatheter Valve for Degenerated Bioprosthesis. THE BASELINE TRIAL.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) serves a growing spectrum of patients with&#xD;
      symptomatic severe aortic stenosis (AS). Approximately 80% of surgical aortic valve&#xD;
      replacements is performed using a bioprosthesis1. Durability of surgical bioprostheses varies&#xD;
      based on the patient's age at the moment of implantation, type and size etc2. TAVI has become&#xD;
      the preferred treatment for degenerated aortic bioprostheses in elderly patients3. The median&#xD;
      time since index surgical aortic valve replacement (SAVR) and for bioprosthetic valve&#xD;
      degeneration is typically 8 - 10 years4-6. TAVI in this setting has proven to have equally&#xD;
      favorable results as in native aortic valves7. Balloon expandable8 and self-expanding9&#xD;
      transcatheter heart valves (THV) can be used in a degenerated bioprosthesis and each have&#xD;
      specific assets and limitations. TAVI in a failed bioprosthesis can cause coronary&#xD;
      obstruction, THV migration, paravalvular leakage and prosthesis patient mismatch. The&#xD;
      SAPIEN-3 / Ultra and EVOLUT R/Pro are the 2 most commonly used THV platforms in contemporary&#xD;
      clinical practice including treatment of failing surgical aortic bioprostheses.&#xD;
&#xD;
      Objective: To compare TAVI with EVOLUT R/Pro vs. SAPIEN-3 / Ultra in terms of device success.&#xD;
&#xD;
      Study design: International multi-center randomized study with 1:1 randomization to TAVI with&#xD;
      SAPIEN-3 / Ultra or Evolut R/Pro.&#xD;
&#xD;
      Study population: 440 patients with a failing surgical aortic bioprosthesis (aortic stenosis&#xD;
      with or without aortic regurgitation) and selected for transfemoral TAVI by heart-team&#xD;
      consensus.&#xD;
&#xD;
      Investigational intervention: Transfemoral TAVI with SAPIEN-3 / Ultra or Evolut R/PRO&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
        1. Primary endpoint is device success at 30 days&#xD;
&#xD;
           Defined by&#xD;
&#xD;
             -  Absence of procedural mortality AND&#xD;
&#xD;
             -  Correct positioning of a single prosthetic heart valve into the proper anatomical&#xD;
                location AND&#xD;
&#xD;
             -  Intended performance of the prosthetic heart valve (no severe prosthesis- patient&#xD;
                mismatch and mean aortic valve gradient &lt; 20 mmHg or peak velocity &lt; 3 m/s, AND no&#xD;
                moderate or severe prosthetic valve regurgitation). Severe prosthesis patient&#xD;
                mismatch is defined by effective orifice area (EOAi) ≤0.65 cm2/m2&#xD;
&#xD;
        2. Safety endpoint at 1 year defined by the composite of all-cause death, disabling stroke,&#xD;
           rehospitalization for heart failure or valve related problems.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device success</measure>
    <time_frame>30 days post transcatheter valve implantation</time_frame>
    <description>Device success, definition modified from VARC-2 criteria:&#xD;
Absence of procedural mortality AND&#xD;
Correct positioning of a single prosthetic heart valve into the proper anatomical location AND&#xD;
Intended performance of the prosthetic heart valve (no severe prosthesis- patient mismatch and mean aortic valve gradient &lt; 20 mmHg or peak velocity &lt; 3 m/s, AND no moderate or severe prosthetic valve regurgitation). Severe prosthesis patient mismatch is defined by effective orifice area (EOAi) ≤0.65 cm2/m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause death, disabling stroke, rehospitalization for heart failure or valve related problems</measure>
    <time_frame>1 year post transcatheter valve implantation</time_frame>
    <description>Safety endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Valve Heart Disease</condition>
  <arm_group>
    <arm_group_label>Evolut R/Pro bioprosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive a self-expanding-valve (either the Evolut R or PRO device)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edwards Sapien S3/Ultra bioprosthesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will receive a balloon-expanding-valve (either the Edwards Sapien S3 or Ultra)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Evolut R/PRO bioprosthesis</intervention_name>
    <description>To compare Evolut R/PRO versus Sapien S3/Ultra in failing surgical bioprostheses</description>
    <arm_group_label>Evolut R/Pro bioprosthesis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards Sapien S3/Ultra bioprosthesis</intervention_name>
    <description>Edwards Sapien S3/Ultra bioprosthesis</description>
    <arm_group_label>Edwards Sapien S3/Ultra bioprosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 65 years&#xD;
&#xD;
          -  Failing surgical aortic bioprosthesis requiring valve replacement and eligible for&#xD;
             transfemoral TAVI with balloon expandable or self-expanding platform per heart team&#xD;
             consensus based on multi-modality imaging assessment (including echocardiography and&#xD;
             multidetector CT).&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not eligible for Transfemoral TAVI with SAPIEN-3 / Ultra and Evolut R/Pro&#xD;
&#xD;
          -  Multi-valve defects requiring intervention&#xD;
&#xD;
          -  Clinically unstable and/or inotropic/vasopressor /mechanical support.&#xD;
&#xD;
          -  Known mural thrombus in the left ventricle&#xD;
&#xD;
          -  Presence of a mechanical aortic valve&#xD;
&#xD;
          -  History of recent (within 1 month) stroke or TIA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Van Mieghem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rutger-Jan Nuis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Erasmus Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rutger-Jan Nuis, MD, PhD</last_name>
    <phone>+31614858291</phone>
    <email>r.nuis@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raj Makkar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raj Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vienna General Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Hengstenberg, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Hengstenberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Paul's and Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Webb, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Wood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Sondergaard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lars Sondergaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Cœur Poumon</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Van Belle, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Van Belle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Von Bardeleben, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephan Von Bardeleben, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Padova</name>
      <address>
        <city>Padua</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giusepe Tarantini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giusepe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rutger-Jan Nuis</last_name>
      <phone>+31614858291</phone>
      <email>r.nuis@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Ocidental</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rui Teles, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rui Teles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital, University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Pilgrim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Pilgrim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Blackman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Blackman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Nicolas van Mieghem</investigator_full_name>
    <investigator_title>Prof. dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

